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Background: We previously reported that immune activation in the spinal dorsal horn contributes to pain induced
by chronic pancreatitis (CP). Targeting immune response in the CNS may provide effective treatments for
CP-induced pain. Recent findings demonstrate that resolvin D1 (RvD1) can potently dampen inflammatory pain. We
hypothesized that intrathecal injection of RvD1 may inhibit pain of CP.
Methods: Rat CP model was built through intrapancreatic infusion of trinitrobenzene sulfonic acid (TNBS). All the
rats were divided into three groups: TNBS, sham, and naïve controls and were further divided for intrathecal RvD1
administration. Pain behavior of rats was tested with von Frey filaments. Anxiety-like behavior and free locomotor
and exploration of rats were evaluated by open field test and elevated plus maze. Pancreatic histology was
evaluated with hematoxylin and eosin staining. Phosphorylation of NMDA receptor and expression of inflammatory
cytokines were examined with Western blot, real-time RT-PCR and ELISA.
Results: Behavioral study indicated that compared to the vehicle control, RvD1 (100 ng/kg) significantly decreased
TNBS-induced mechanical allodynia at 2 h after administration (response frequencies: 49.2 ± 3.7% vs 71.3 ± 6.1%),
and this effect was dose-dependent. Neither CP nor RvD1 treatment could affect anxiety-like behavior. CP or RvD1
treatment could not affect free locomotor and exploration of rats. Western blot analysis showed that compared
with that of naïve group, phosphorylated NR1 (pNR1) and pNR2B in TNBS rats were significantly increased in the
spinal cord (pNR1: 3.87±0.31 folds of naïve control, pNR2B: 4.17 ± 0.24 folds of naïve control). Compared to vehicle
control, 10 ng/kg of RvD1 could significantly block expressions of pNR1 (2.21 ± 0.26 folds of naïve) and pNR2B (3.31
± 0.34 folds of naïve). Real-time RT-PCR and ELISA data showed that RvD1 (10 ng/kg) but not vehicle could
significantly block expressions of TNF-alpha, IL-1beta and IL-6. In addition, RvD1 did not influence pain behavior,
NMDA receptor phosphorylation or cytokines production in sham-operated rats.
Conclusions: These data highly suggest that RvD1 could be a novel and effective treatment for CP-induced
chronic pain.
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Pain is the primary complain of patients with visceral
organ disorders. Recurrent and serious abdominal pain is
one of the most common symptoms in chronic pancrea-
titis (CP) [1]. Lots of studies have been performed to ex-
plore the underlying mechanisms of CP-induced pain,
while most of the work is focused on pathological changes
in the pancreas tissue [2]. However, it is reported that pain
processing in the central nervous system (CNS) is also ab-
normal in CP-related neuropathic pain disorders [3]. It is
also suggested that pancreatic neuropathy could bring
“neural remodeling” [4]. These results highly suggest that
neuroplastic changes in the CNS are probably important
contributors to the CP-induced chronic pain. We previ-
ously showed that astrocytes were activated and inflamma-
tory cytokines were up-regulated in the spinal cord in a
rat CP model induced by intrapancreatic infusion of trini-
trobenzene sulfonic acid (TNBS) [5]. These data suggest
that neuron-immune interactions in the spinal dorsal horn
play a pivotal role in neuroplastic changes and CP-
induced pain. More importantly, targeting immune re-
sponse in the CNS may provide some novel and effective
treatments for CP-induced pain.
Resolvins are biosynthesized from omega-3 fatty acids
docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA), and show remarkable potency in resolving inflam-
mation-related diseases [6]. Recent studies suggested that
resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-
docosahexaenoic acid, RvD1) exhibited potent anti-
inflammatory actions in rodent models of inflammation
[7]. Interestingly, RvD1 also reduced pain response in
animal models of inflammatory pain. Intraplantar RvD1
post-treatment reduced complete Freund’s adjuvant (CFA)-
induced mechanical hyperalgesia and allodynia [8]. In
addition, intrathecal post-treatment with RvD1 also rapidly
reduced CFA-induced heat and mechanical hypersensitivity
[9]. These data suggest that RvD1 may provide effective
anti-allodynia treatment on pain. However, whether and
how RvD1 works on inflammatory visceral pain, such as
pain of CP, is to be determined.
In the present study, we first investigated the behav-
ioral changes of rats with CP following intrathecal injec-
tion of RvD1. Then we detected the phosphorylation of
NMDA receptors, which play essential roles in central
sensitization of pain signal processing. We further
explored the production of inflammatory cytokines in
the spinal cord of rats with CP after RvD1 treatment.
Results
Intrathecal RvD1 injection attenuated CP-induced
mechanical allodynia
We previously reported that TNBS could successfully in-
duce histological changes of pancreas at 5 w after surgery,which included acinar atrophy, inflammatory infiltration,
and periductular and intralobular fibrosis, stromal prolifera-
tion (Figure 1). CP-induced persistent mechanical allodynia
is characterized by increase of abdomen response frequen-
cies (RFs) [3,10]. We previously observed that rats with CP
showed persistent mechanical hypersensitivity in the abdo-
men [11]. The mechanical allodynia was evident 1 w after
TNBS infusion and persistent up to 5 w (data not shown).
To examine the anti-allodynia effect of RvD1 on CP-
induced neuropathic pain, we intrathecally injected RvD1
at 5 w after TNBS infusion and observed the behavioral
consequences. Compared to the vehicle control group,
RvD1 (100 ng/kg) significantly decreased RFs at 2 h after
administration (49.2 ± 3.7% vs 71.3 ± 6.1%, P < 0.05,
Figure 2A). The anti-allodynia effect of RvD1 lasted at
least for 12 h and almost disappeared at 24 h after admin-
istration. Then we tested the pain behavior with different
strength of von Frey filaments (2.29, 2.75, 6.76, 16.6, 40.7,
69.2 and 120 mN) at 4 h after administration to further
confirm the above data. Compared to the vehicle, RvD1
(100 ng/kg) significantly decreased RFs stimulated by most
of the von Frey filaments (P < 0.05, Figure 2B). We further
observed that TNBS-induced allodynia was remarkably
attenuated by RvD1, in a dose-dependent manner
(Figure 2C). However, RvD1 did not influence RFs of sham
operated rats. There was no significant difference in RFs
between sham-vehicle and sham-RvD1 group, at any time
points after administration, or stimulated by any strength
of filaments.
In addition, elevated plus-maze test showed that the
percentage of open-arm time and entries in rats of CP
showed no significant difference compared to the sham
rats. Furthermore, after treatment with RvD1, no signifi-
cant difference could be detected in the percentage of
open-arm time and entries between different groups
(Figure 3A and B), suggesting that neither CP nor RvD1
treatment could affect anxiety-like behavior. Open field
test showed no significant difference in the percentage
of time in the inner squares or the total number of
squares crossed could be detected among all the groups,
after different treatments (Figure 3C and D). These data
indicated that CP or RvD1 treatment could not affect
free locomotor and exploration of rats.
RvD1 reversed CP-induced phosphorylation of NMDA
receptor NR1 and NR2B subunit in the thoracic spinal
dorsal horn
Recent studies suggested that resolvins could suppress
the TNF-alpha-evoked NMDA receptor hyperactivity in
spinal dorsal horn neurons [9]. Western blot analysis
indicated that in naïve and sham operated rats, pNR1
and pNR2B expressions in the thoracic spinal dorsal
horn were very low (Figure 4). Compared with that of
naïve or sham group, pNR1 and pNR2B in TNBS-
Figure 1 Trinitrobenzene sulfonic acid (TNBS) infusion-induced rat chronic pancreatitis. (A-B) HE staining of the pancreas in (A) normal
and (B) TNBS infused rats. (C) The severity of CP was morphological assessed by semiquantitative scoring: graded glandular atrophy (0–3);
intralobular, interlobular and periductal fibrosis (0–3); inflammatory cells infiltrations (0–3). BL: baseline. * P<0.05 compared with that of naïve
group.
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(pNR1: 3.87±0.31 folds of naïve control, pNR2B: 4.17 ±
0.24 folds of naïve control, P<0.05, Figure 4). Intrathecal
injection of RvD1 (500 ng/kg) did not influence phos-
phorylation of NR1 (0.89 ± 0.12 folds of naïve) or NR2B
(1.09 ± 0.21 folds of naïve) in sham operated rats. How-
ever, compared to vehicle control, 10 ng/kg of RvD1
could significantly block expressions of pNR1 (2.21 ±
0.26 folds of naïve) and pNR2B (3.31 ± 0.34 folds of
naïve). In addition, 500 ng/kg of RvD1 could further de-
crease the phosphorylation of NR1 (1.63 ± 0.22 folds of
naïve) or NR2B (1.93 ± 0.33 folds of naïve). In contrast,
the expressions of total NR1 or NR2B were unchanged,
either after TNBS infusion, or treated with RvD1. With
double immunofluorescent histochemistry, we observed
that NR1 and NR2B subunits of NMDA receptor were
exclusively expressed on neurons, but not on astrocytes
or microglia in the thoracic spinal dorsal horn (Figure 5).
These data indicated that RvD1 could significantly
modulate neuronal NMDA receptor activities and influ-
ence nociceptive transmission.
RvD1 significantly reversed CP-induced cytokines
expression
We previously observed that various cytokines were signifi-
cantly up-regulated in the spinal dorsal horn of pancreaticrats [11]. Considering the anti-inflammatory nature of
RvD1, we then examined whether intrathecal injection of
RvD1 could block the up-regulation of inflammatory cyto-
kines in the spinal dorsal horn of CP rats. A significant up-
regulation of cytokines was observed after CP-induced
chronic pain. Real-time PCR study showed that in the
TNBS-vehicle group, we observed significant increases of
TNF-alpha (3.11 ± 0.25 folds of naïve, P<0.05), IL-1beta
(2.87 ± 0.31 folds, P<0.05), and IL-6 (1.92 ± 0.12 folds,
P<0.05) compared with those of naïve and sham groups.
Intrathecal injection of RvD1 (10 ng/kg) but not vehicle
could significantly block expressions of TNF-alpha (2.39 ±
0.21 folds of naïve, P<0.05), IL-1beta (2.21 ± 0.26 folds,
P<0.05), and IL-6 (1.62 ± 0.15 folds, P<0.05). In addition,
500 ng/kg of RvD1 could further decrease the TNF-alpha
(1.78 ± 0.35 folds of naïve, P<0.05), IL-1beta (1.63 ± 0.25
folds, P<0.05), and IL-6 (1.30 ± 0.28 folds, P<0.05)
(Figure 6A). ELISA analysis showed similar data. TNBS in-
fusion induced a remarkable increase of TNF-alpha (2.46 ±
0.21 folds of naïve, P<0.05), IL-1beta (2.01 ± 0.12 folds,
P<0.05), and IL-6 (2.68 ± 0.28 folds, P<0.05) compared
with those of naïve groups. In addition, RvD1 could signifi-
cantly decrease those expressions (Figure 6B). These data
indicated that intrathecal injection of RvD1 could signifi-
cantly block TNBS-infusion induced up-regulation of in-
flammatory cytokines in the spinal dorsal horn.
Figure 2 Intrathecal administration of resolvin D 1 (RvD1)
attenuates mechanical allodynia induced by CP. (A) Response
frequencies to mechanical stimulation of the abdomen with the 40.7
mN of von-Frey filaments at different time points after RvD1 (or
vehicle) administration. BL: baseline. (B) Response frequencies to
mechanical stimulation of the abdomen with von-Frey filaments of
various strengths at 4 h after RvD1 (or vehicle) treatments. *, #
P<0.05 compared with that of sham-vehicle or TNBS-vehicle group,
respectively. (C) TNBS-induced allodynia was significantly attenuated
by RvD1 in a dose-dependent manner. * P<0.05 compared to 100
ng/kg group.
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RvD1 is a kind of resolvins, which were originally iso-
lated in exudates formed in the resolution phase of acute
inflammation in both rodents and humans [12]. Recent
studies suggest that resolvins could be effective treat-
ments for inflammatory and postoperative pain [8,9]. It
is suggested that resolvins could reduce inflammatory
pain via peripheral and central actions. Intraplantar
RvD1 pretreatment reduces formalin-induced spontan-
eous pain and prevents carrageenan-induced hyperalge-
sia [8]. Intrathecal post-treatment with RvD1 could
reduce CFA-induced mechanical hypersensitivity [9]. In
the present study, we observed an obvious central effect
of RvD1 on CP pain. Recent studies suggest that in
addition to the inflammatory response in the inflamed
tissue, central immune response is also critical in the
process of chronic pain [13,14]. In the case of CP-
induced pain, we previously observe that astrocytes are
remarkably activated in the spinal dorsal horn and ac-
tively contribute to pain behavior [5]. We further find
that toll-like receptor 3 is also up-regulated and med-
iates astrocytic activation [11]. A recent study also
reports that microglia are also activated in the dorsal
horn of rats with CP [15]. These findings support our
notion that central inflammatory response plays pivotal
roles in CP-induced pain. And that is probably how
intrathecal injection of RvD1 works on the CP pain.
However, the role of intra- or peri-pancreatic adminis-
tration of RvD1 on CP and pain behavior is to be deter-
mined. In the present study, we administered RvD1
intrathecally at very low doses, which could not easily
affect inflammation in the pancreas, especially when we
injected RvD1 at 5w after induction of inflammation.
That is why we believe that the analgesic effect of RvD1
is directly through spinal dorsal horn.
We then explore the underlying mechanism of the
anti-allodynia effect of RvD1. Gαi-associated ChemR23
is the receptor for resolvins [16]. It is indicated that
ChemR23 has a broad expression in various cell types,
including spinal dorsal horn neurons [17]. Activation of
NMDA receptors in the spinal neurons plays an essential
role in central sensitization and thus chronic pain [18].
Functional NMDA receptors are heteromeric complexes
including the NR1 subunit and one or more of the
NR2A-D subunits [19]. NR2B subunit has a relatively
restricted distribution in the superficial spinal dorsal
horn which has more important correlations with noci-
ceptive transmission [20]. It is reported that intrathecal
injection of NMDA receptor antagonists could inhibit
CP pain [21]. In the present study, we observed a signifi-
cant up-regulation of phosphorylation of NMDA recep-
tor NR1 and NR2B subunit in the thoracic spinal dorsal
horn neurons. This is by far the first direct evidence of
NMDA receptor phosphorylation in the pain of CP.
Figure 3 Effects of TNBS infusion and RvD1 administration on elevated plus-maze test and open field. Neither TNBS infusion nor RvD1
administration affected the percentage of time the test rats spent in the open arm and percentage of open arm entries in the EPM test (A and B), or
percentage of time in the inner square, total number of squares in the OFT (C and D). BL: baseline.
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verse CP-induced NMDA receptor phosphorylation. It is
reported that resolvins could significantly block NMDA
receptor phosphorylation induced by TNF-alpha [9].
Thus, it is conceivable that RvD1 may abrogate central
sensitization via inhibiting phosphorylation of NMDA
receptor in the spinal dorsal horn of rats with CP.
Tissue inflammation produces cytokines in spinal glial
cells, which drive central sensitization by increasing ex-
citation and decreasing inhibition in dorsal horn neu-
rons [22]. It has been reported that spinal microglia
contribute to the genesis of pain induced by CP [15].
Interestingly, the resolvins receptor ChemR23 is also
expressed on microglia [17]. It is reasonable to suggest
that RvD1 may also dampen pain through inhibiting glialactivation and production of inflammatory cytokines. In
the present study, we observed that RvD1 treatment
could significantly inhibit production of spinal TNF-alpha,
IL-1beta, and IL-6 induced by CP. We previously observed
in a neuropathic pain model that spinal IL-1beta is mainly
released by spinal astrocytes but not by microglia [23]. So
probably, spinal astrocytic activation could also be ham-
pered by RvD1 administration.
Importantly, it should be mentioned that the inhibitive
effect of RvD1 on phosphorylation of NMDA receptors
and on production of cytokines could be tightly related.
It is reported recently that NR2B subunit phosphoryl-
ation may contribute to the release of cytokines from
spinal astrocytes [23]. In addition, IL-1beta could posi-
tively modulate NMDA receptor function [24]. This
Figure 4 RvD1 reverses phosphorylation of NMDA receptor subunit NR1 (A) and NR2B (B). Data are expressed as fold changes of naïve
control group. Compared with that of naïve or sham group, pNR1 and pNR2B in TNBS-vehicle were significantly increased in the spinal cord.
Compared to vehicle control, RvD1 could significantly block expressions of pNR1 and pNR2B. *, # P<0.05 compared to sham-vehicle or TNBS-
vehicle group, respectively.
Figure 5 Colocalization of NMDA receptor subunits NR1 (A1-I1) and NR2B (A2-I2) with neuronal and glial markers in dorsal horn.
Immunofluorescent colocalization of green reaction products for NR1/NR2B and red products for the neuronal marker NeuN, the astrocyitc
marker GFAP, and the microglial marker OX42. Scale bars = 300 μm in I1 and I2, applied in A1-I1 and A2-I2, respectively.
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Figure 6 RvD1 inhibits cytokine expressions revealed by real-
time PCR (A) and ELISA (B). Changes of TNF-alpha, IL-1beta, and
IL-6 at mRNA and protein levels were determined in the T10 region
of the dorsal spinal cord of CP or sham rats. Data are expressed as
fold changes of naïve control group. TNBS infusion induced a
remarkable increase of TNF-alpha, IL-1beta, and IL-6 compared with
those of naïve groups. In addition, RvD1 could significantly decrease
those expressions. *, # P<0.05 compared to sham-vehicle or TNBS-
vehicle group, respectively.
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inflammation on nociception and makes it more difficult
to develop a clinical therapy for pain of CP [13]. Inter-
estingly, RvD1 could block these two key factors and
thus block the positive feedback circuit. It thus assures
the preonunced anti-allodynia effect of RvD1 on CP-
induced chronic pain.
Conclusions
We demonstrate that intrathecal injection of RvD1 could
significantly attenuate pain of CP, in a dose-dependent
manner. We further show that intrathecal injection of
RvD1 could remarkably reverse NMDA receptor phos-
phorylation and cytokines expression in the spinal dorsal




Male Sprague–Dawley rats (250-300 g) were used in the
present study. All experimental procedures received ap-
proval from the Animal Use and Care Committee for
Research and Education of the Fourth Military Medical
University (Xi’an, P. R. China) and also the ethical guide-
lines to investigate experimental pain in conscious animals.
TNBS-induced rat model of pancreatitis was built
according to our previous studies [5,11]. Briefly, the
common bile duct was closed temporarily near the liver
with a small vascular clamp. A blunt 28 gauge needle
with polyethylene (PE10) tubing attached was inserted
into the duodenum. TNBS solution (0.5 ml, 2%) in 10%
ethanol in phosphate buffered saline (PBS, pH 7.4) was
infused into the pancreatic duct over a period of 2–5
min. The hole in the duodenum was sutured and the
vascular clamp was removed restoring the bile flow. All
the procedures in the sham group were same as that in
the TNBS group, except that the same volume of normal
saline instead of TNBS was infused into the duct.
Administration of drugs
Laminectomy was performed at the level of the thoracic
vertebrae under pentobarbital anesthesia (45 mg kg-1, i.p.).
A PE10 catheter (I.D. 0.28 mm and O.D. 0.61 mm) was
passed caudally from the T9 to the T12 level of the spinal
cord. Two centimeters of the free ending was left exposed
in the upper thoracic region. Rats were allowed to recover
for a period of 3 - 5 days before further use. Only the ani-
mals judged as neurologically normal and that showed
complete paralysis of the tail and bilateral hind legs after
administration of 2% lidocaine (10 μl) through the intra-
thecal catheter were used for the following experiments.
RvD1 (Cayman Chemical Co., Ann Arbor, MI, USA) was
stored at -80°C. Immediately before use, RvD1 was directly
diluted to working concentration with the bath solution
and briefly sonicated.
All the rats were divided into three groups: TNBS
(n = 42), sham (n =30), and naïve controls (n = 6). At 5
w after TNBS model, rats in TNBS (n = 36) and sham
group (n = 24) were each further divided for drug injec-
tion: TNBS-RvD1 (or sham- RvD1) group: RvD1 was
intrathecally injected on TNBS-infused (10 ng/kg, n= 6;
100 ng/kg, n= 12; or 500 ng/kg, n = 6; total volume = 10
μl) or sham operated rats (500 ng/kg, n =12); TNBS-vehicle
(or sham-vehicle) group: 10 μl of bath solution was injected
on TNBS-infused (n = 12) or sham operated rats (n = 12).
After behavioral tests, all the rats including naïve, TNBS,
and sham rats (n = 6 each) without intrathecal injection
were sacrificed for further experiments.
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Behavioral testing was performed according to our proto-
col reported previously [5]. Before test, the belly skin was
shaved and area designated for stimulation was marked.
Rats were placed in a plastic cage with a mesh floor and
were given 30 min for adaptation. In the time course
study, pain behavior was evaluated before and 2 h, 4 h, 12
h, 24 h after drug injection with a single strength of von
Frey filaments (Stoelting, Kiel, WI, USA) (40.7 mN). In
the force-related study, pain behavior was evaluated at 4 h
after drug injection with a series of von Frey filaments
(2.29, 2.75, 6.76, 16.6, 40.7, 69.2 and 120 mN). Von Frey
filaments were applied from underneath through the mesh
floor, in ascending order to the abdominal area at different
points on the surface. A single trial consisted of 10 appli-
cations each for 1–2 s with a 15 s interval between appli-
cations allow the animal to cease any response and return
to a relatively inactive position. A positive response con-
sisted of the rat raising its belly (withdrawal response).
The data were expressed as a percentage of the positive
responses with each filament for each rat.
Elevated plus-maze test
Elevated plus-maze test was performed before and 4 h
after RvD1 treatment to evaluate whether CP-induced
pain/RvD1 could influence anxiety-like behavior. After
adaptation for 1 d, rats were placed in the middle of maze
apparatus, and the behavior has been recorded by a video
camera for 5 min. Data were expressed as the percentage
of time spent in the open arms [100 × (time in the open
arms/total time spent in both arms)] and percentage of
open-arm entries as an index of the anxiety-like behavior
and a total number of open arm and closed-arm entries as
an index of overall locomotor activity. Only entering into
one arm with all four paws was defined as an entry. The
maze was cleaned after each trial to prevent olfactory cues
from affecting the behavior.
Open field test
Open field test was applied before and 4 h after RvD1
treatment to analyze the free locomotor and exploration of
rats after different treatments. Animals were placed into
one corner of the open field (100 cm × 100 cm × 48 cm).
Movement of the animal in the area during the 5-min test-
ing session was recorded. After 5 min, the animal was
removed to the home cage, and the open field area was
cleaned. Exploration was defined as the time spent in the
inner 6 × 6 squares, whereas overall activity was defined as
the number of squares crossed during the testing session.
Pancreatic histology
Rats were deeply anesthetized with sodium pentobarbital
(60 mg/kg, i.p.) and the pancreas was obtained and then
fixed in 4% paraformaldehyde in phosphate buffered(PB, pH 7.4) at 4°C overnight. Pancreatic tissue was then
transferred to progressive xylene washes and was placed
in cassettes and embedded in paraffin. Paraffin blocks
were cut in 5-μm sections and stained with hematoxylin
and eosin. Histological sections were analyzed by a path-
ologist in a double blinded manner. The severity of CP
was assessed by semiquantitative scores according to:
graded glandular atrophy (0–3); inflammatory cells infil-
trations (0–3); intralobular, interlobular and periductal
fibrosis (0–3) [25,26].
Western blot
All animals were rapidly sacrificed and the thoracic (T) 10
spinal cord was rapidly harvested and then was frozen on
the dry ice. Then the spinal dorsal horn was quickly
micro-dissected. Spinal tissue was then homogenized in
SDS sample buffer (10 ml/mg tissue) with a mixture of
proteinase and phosphatase inhibitors (Sigma). The elec-
trophoresis samples were heated at 100°C for 5 min and
loaded onto 10% SDS-polyacrylamide gels with standard
Laemmli solutions (Bio-Rad Laboratories, CA, USA). The
proteins were electroblotted onto a polyvinylidene difluor-
ide membrane (PVDF, Immobilon-P, Millipore, Billerica,
MA, USA). The membranes were placed in a blocking so-
lution containing Tris-buffered saline with 0.02% Tween-20
(TBS-T) and 3% non-fat milk for 1 h, and incubated over-
night under gentle agitation with primary antibodies: rabbit
anti-phosphorylated NR1 (pNR1, 1:1000; Millipore, Billerica,
MA, USA), rabbit anti-NR1 (1:500; Millipore), rabbit anti-
phosphorylated NR2B (pNR2B, 1:500; Millipore), rabbit
anti-NR2B (1:500; Millipore), and mouse anti-beta-actin
(1:3000; Millipore). Bound primary antibodies were
detected with the anti-rabbit or anti-mouse horseradish
peroxidase (HRP)-conjugated secondary antibody (1:5,000;
Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA).
Between each step, the immunoblots were rinsed with
TBS-T. All reactions were detected by the enhanced
chemiluminescence (ECL) detection method (Amersham).
The densities of protein blots were analyzed with Lab-
works Software (Ultra-Violet Products, UK). The densities
of target proteins and beta-actin were quantified with
background subtraction. Target protein levels were nor-
malized against beta-actin levels and expressed as relative
fold changes compared to the naïve control group.
Double-labeling immunofluorescent histochemistry
The rats were deeply anesthetized and perfused transcar-
dially with 100 mL of 0.01 M phosphate-buffered saline
(PBS, pH 7.4) followed by 500 mL of 4% paraformalde-
hyde in 0.1 M phosphate buffer (pH 7.4). After the
perfusion, the T10 segments were harvested and cryopro-
tected in 30% sucrose overnight. The transverse sections
were cut on a cryostat at a thickness of 30 μm. The sec-
tions were incubated overnight with a mixture of rabbit
Table 1 Primers sequence for the rat genes characterized
in this experiment
Genes Primers Accession number
TNF-alpha Forward primer 5’-TGATCGGTCCC
AACAAGG A-3’
AY427675
Reverse primer 5’-TGCTTG GTG
GTTTGCTACGA-3’
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(1:3000; Millipore), or mouse anti-glial fibrillary acidic
protein (GFAP) (1:5000; Millipore), or mouse anti-OX42
(1:500; Millipore); or with a mixture of rabbit anti-NR2B
(1:500, Millipore) with mouse anti-NeuN (1:3000;
Millipore), or mouse anti-GFAP (1:5000; Millipore), or
mouse anti-OX42 (1:500; Millipore). The sections were
then washed for 3 times in 0.01 M PBS (10 min each) and
then incubated for 2 h at RT with the corresponding sec-
ondary antibody: Alexa Fluor 488-conjugated goat anti-
rabbit IgG (1:200; Molecular Probes, Eugene, OR, USA)
and Alexa Fluor 594-conjugated goat anti-mouse IgG
(1:800; Molecular Probes). Images were obtained using a
confocal laser microscope (FV1000; Olympus, Tokyo,
Japan) and Digital images were captured with Fluoview
1000 (Olympus).Real-time RT-PCR
After behavioral tests, rats were rapidly sacrificed and
the T10 spinal cord was rapidly harvested and then the
spinal dorsal horn was quickly micro-dissected on the
dry ice. RNA was extracted with Trizol (GIBCO/BRL
Life Technologies Inc., Grand Island, NY, USA). Com-
plementary DNA (cDNA) was synthesized with oligo
(dT)12-18 using Superscript
™ III Reverse Transcriptase
for RT-PCR (Invitrogen, Carlsbad, CA, USA). The pri-
mers used were shown in Table 1. One microgram of
RNA was used to prepare cDNA using the SYBRW Pre-
mix Ex Taq™ (Takara, Tokyo, Japan). Real-time PCR was
then performed in a detection system (Applied Biosys-
tems, Foster City, CA, USA). The amplification protocol
was: 3 min at 95°C, followed by 40 cycles of 10 s at 95°Cfor denaturation and 45 s at 60°C for annealing and ex-
tension. All experiments were repeated for 3 times and
in each experiment, PCR reactions were done in tripli-
cate. Target cDNA quantities were estimated from the
threshold amplification cycle number (Ct) using Se-
quence Detection System software (Applied Biosystems).
GAPDH was served as an endogenous internal standard
control for variations in RT-PCR efficiency.
ELISA
In order to determine protein expression of TNF-alpha,
IL-1beta and IL-6, rats were rapidly sacrificed and the T10
spinal cord was rapidly harvested and then the spinal dor-
sal horn was quickly micro-dissected and homogenized in
lysis buffer containing protease inhibitors, and the insol-
uble pellet was separated out by centrifugation. TNF-alpha,
IL-1beta and IL-6 concentration in the supernatants were
measured spectrophotometrically using a commercially
available ELISA kit according to the manufacturer’s
instructions (BioSite, Paris, France). TNF-alpha, IL-1beta
and IL-6 were measured at 450 nm using a Fluoroskan
Ascent cytofluorimeter (Thermo Electron, Milford, MA,
USA), and the concentrations were calculated on the basis
of relative recombinant standard curve. All samples were
processed in triplicate. Data were obtained from 3 inde-
pendent experiments.
Data analysis
All data were collected by experimenters blind to the
surgery and treatments and statistical analysis was done
by using SPSS software (version 12.0). Data were
expressed as means ± standard error of the mean
(means ± S.E.M.). Repeated measures ANOVA (with
Bonferroni confidence interval adjustment) were used
and conducted for data of pancreatic pathology, Western
blot and real-time PCR analysis. Dunnett’s C post hoc
test, assuming the variances were not equal, was
employed whenever appropriate and significance was set
at 0.05 for all statistical tests.
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